Engineered <i>Bacillus subtilis</i> as oral probiotics to target circulating lactic acid.

Engineered Bacillus subtilis as oral probiotics to target circulating lactic acid.

Yang, Mengdi; Hutchinson, Noah; Yin, Jianing; Guan, Ming; Wang, Zongqi; Chen, Peiru; Yang, Shaobo; Crane, Justin D; Zhang, Ke; Li, Jiahe.

Afiliação

Yang M; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States.
Hutchinson N; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, United States.
Yin J; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States.
Guan M; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States.
Wang Z; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, United States.
Chen P; Department of Chemistry, Northeastern University, Boston, MA, 02115, United States.
Yang S; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States.
Crane JD; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139.
Zhang K; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States.
Li J; Department of Chemistry, Northeastern University, Boston, MA, 02115, United States.

bioRxiv ; 2023 Dec 01.

Article em En | MEDLINE | ID: mdl-38076834

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article